logo

For the Inventor, By the Inventor

Beijing, China

Chengyuan Lu

This inventor holds 10 USPTO granted patents and 10 published patent applications. Top assignees: Eucure (Beijing) Biopharma Co., Ltd., Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. Active years: 2021-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Chengyuan Lu. Retrieved from https://idiyas.com/inventor/chengyuan-lu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 100.0

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:

goldMedal8 out of 8 
 
Eucure (Beijing) Biopharma Co., Ltd.
 patents
silverMedal2 out of 33 
 
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
 patents

Years Active: 2021-2024

Loading Chart...
10 patents (USPTO):Explore Patents
1. 12180281 - Anti-PD-1 antibodies and methods of treating cancer (2024-12-31),
2. 12134653 - Anti-CD40 antibodies and uses thereof (2024-11-05),
3. 12054547 - Anti-CTLA4 antibodies and uses thereof (2024-08-06),
4. 11999790 - Anti-OX40 antibodies and uses thereof (2024-06-04),
5. 11352429 - Anti-PD-1 antibodies and uses thereof (2022-06-07),
6. 11292849 - Anti-TNFRSF9 antibodies and uses thereof (2022-04-05),
7. 11155625 - Anti-PD-1 antibodies and uses thereof (2021-10-26),
8. 11142582 - Anti-CD40 antibodies and uses thereof (2021-10-12),
9. 11034764 - Anti-CTLA4 antibodies and uses thereof (2021-06-15),
10. 10934365 - Anti-OX40 antibodies and uses thereof (2021-03-02),

Title: Innovations by Chengyuan Lu in Cancer Treatment

Introduction

Chengyuan Lu is a prominent inventor based in Beijing, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of 10 patents, focusing primarily on innovative treatments for cancer. His work has the potential to impact the lives of many patients suffering from various forms of cancer.

Latest Patents

Among his latest patents are groundbreaking developments in anti-PD-1 antibodies and anti-CD40 antibodies. The anti-PD-1 antibodies are designed to target the Programmed Cell Death Protein 1, offering new methods for treating cancer. Additionally, his anti-CD40 antibodies focus on the TNF Receptor Superfamily Member 5, providing further avenues for therapeutic applications in oncology.

Career Highlights

Chengyuan Lu has worked with notable companies in the biopharmaceutical sector, including Eucure Biopharma Co., Ltd. and Biocytogen Pharmaceuticals Co., Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.

Collaborations

Chengyuan has collaborated with several professionals, including Chen Wang and Chunyan Dong, enhancing the scope and impact of his research. These collaborations have fostered a dynamic environment for innovation and development in cancer therapies.

Conclusion

Chengyuan Lu's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…